Synaffix Expands Partnership Horizon with Boehringer Ingelheim
January 9, 2025 - 17:10
In a significant move to enhance its portfolio, Synaffix, a leader in antibody-drug conjugate (ADC) technology, has entered into a new licensing agreement with Boehringer Ingelheim. This partnership allows Boehringer to leverage Synaffix's advanced ADC technologies for a specified number of cancer targets, although the exact details regarding the number of targets remain confidential.
This agreement marks a strategic step for Synaffix as it continues to build on its momentum from last year, when it secured several partnerships. Additionally, Synaffix has expanded its collaboration network by forming a technology licensing deal with Mitsubishi Tanabe Pharma in Japan. These developments underscore Synaffix's commitment to advancing cancer treatment options through innovative ADC technologies.
As the landscape of cancer therapeutics evolves, this collaboration with Boehringer Ingelheim is poised to accelerate the development of novel ADC therapies, potentially leading to more effective treatment solutions for patients battling cancer.
MORE NEWS
April 20, 2026 - 19:27
Navigating the AI Regulatory Maze: Experts Weigh In on Innovation and PolicyThe rapid advancement of artificial intelligence has sparked a complex global debate on how best to govern the technology. According to analysts Anna Viñals Musquera and Scott Babwah Brennen, a...
April 20, 2026 - 10:07
New technology is increasing the speed and depth of cyber attacksFinancial services groups are having to adapt rapidly to a changing threat landscape, as new technology dramatically increases the speed and depth of cyber attacks. The industry, a perennial target...
April 19, 2026 - 18:00
Why were there fewer snow days this school year? It’s another aftereffect of the pandemic.The familiar ritual of waking up to a snow-covered world and the joyous announcement of a canceled school day is becoming increasingly rare. Across many districts, the traditional snow day has been...
April 19, 2026 - 07:31
Is It Too Late To Consider Align Technology (ALGN) After Recent Share Price Rebound?After a significant rebound, investors are questioning whether Align Technology`s stock still holds potential or if the window for substantial gains has closed. The company`s share price, now...